Participated · Equity · Jul 2026

Dogtooth Technologies develops autonomous robotic harvesting systems that combine advanced computer vision, artificial intelligence and precision robotics to identify ripe fruit and harvest delicate crops at commercial scale. The company positions itself at the forefront of embodied AI by applying artificial intelligence to physical machines operating in real-world agricultural environments. Dogtooth has demonstrated commercial readiness and recently delivered systems to Dyson Farming. It aims to help growers address persistent labour shortages, improve operational resilience and increase harvesting capacity. The company plans to expand commercial deployments across the UK and internationally and to strengthen its technology platform. Its recent £14 million growth financing — a mix of equity, grants and a venture leasing facility — is intended to accelerate that commercial rollout and adoption.

Led · Equity · Dec 2025

Edinburgh-based Sofant Technologies is engineering low-power radio-frequency (RF) MEMS beam-forming antennas designed to improve the efficiency of satellite communications and future 5G and 6G networks. Its proprietary architecture aims to cut power consumption and size while boosting performance, making it attractive for defence, aerospace, satellite, and high-performance enterprise markets. The company has spent an extended period in research and development, refining its breakthrough hardware platform. With its latest financing, Sofant intends to transition from R&D into full commercial launch, scaling production and deployment of its technology. Management believes the solution represents a step-change in wireless system design, potentially redefining what is possible in low-power, high-performance connectivity. Financially, Sofant has just secured £6.25 million in fresh equity capital to fund this commercial rollout, underscoring investor confidence in its market potential.

Led · Debt Financing · Dec 2025

Wanda Health (also referred to as Wanda Connected Health) offers a digital remote patient monitoring platform that tracks individuals with chronic conditions such as diabetes and heart disease outside clinical settings. Its system combines connected devices, mobile apps and an analytics layer called the Insights Engine to surface actionable guidance for clinicians and users. Recent product releases include support programmes for GLP-1 weight-loss drug patients and an updated cardiometabolic app. Management reports that the company has beaten larger competitors to land several multi-million-dollar contracts and is experiencing double-digit monthly revenue growth. Wanda expects to exceed US$5 million in annual recurring revenue by the end of 2026. The firm is channelling new capital into accelerating work with major U.S. customers, advancing product development and scaling commercial execution. Post-round, EMV Capital values its 16.5 % stake in Wanda at £1.7 million, while third-party assets introduced by EMV now hold 29.6 % worth about £3.1 million.

Participated · Equity · Nov 2024

EpiBone develops personalized skeletal tissue products for bone and cartilage reconstruction using autologous and allogeneic stem cells, 3D bioprinting, and bioreactor systems. The company’s core technologies enable patient-specific constructs designed to match a patient’s unique anatomy. EpiBone is advancing a pipeline of skeletal tissue products intended to shorten recovery times and improve outcomes for injuries and degenerative conditions. Leadership under CEO and co-founder Dr. Nina Tandon is guiding product development and strategy. The company reports total capital raised of $1M and recently secured an additional funding round led by Kendall Capital Partners with support from LifeSpan Vision Ventures and EMV Capital to accelerate pipeline work. EpiBone is pursuing global expansion opportunities, including markets such as Thailand and the United Arab Emirates. EpiBone is a privately held regenerative medicine company developing personalized bone, cartilage, and compound (bone and cartilage) products using a proprietary bioreactor and a three-step process to regenerate human bone. Its lead bone product, EB-CMF, is in Phase 1 human trials following FDA IND clearance in 2019 for a Phase 1/2 trial targeting ramus continuity defects in the mandible. The platform starts with a CT scan to design a precise scaffold, constructs a custom bioreactor, and infuses the scaffold with the patient’s stem cells to grow a personalized graft. The company traces its technology to roughly 20 years of foundational research in orthopedic tissue engineering and has received grants and early funding. In November 2020 Prof. Robert S. Langer was appointed to EpiBone’s board, and the company has previously received initial funding (2014) from the Partnership Fund for New York City and Breakout Labs. Recent financing is intended to take the company through to a scale-up round expected in late 2022 and to accelerate pipeline development.

Led · Equity · Sep 2023

Q-Bot develops AI- and robotics-driven systems that deploy continuous layers of spray-foam insulation beneath suspended timber and concrete floors to reduce heat loss and block cold draughts. Founded in 2012 and based in London, the company has operated for over ten years and has installed its solution in more than 4,000 properties across the UK and Europe. Q-Bot works with over 50 registered social housing providers, energy companies including E.ON and British Gas, and a network of accredited installers and property agents. It is a supplier to UK government schemes including the Green Homes Local Authority Delivery Scheme, the Social Housing Decarbonisation Fund, the Great British Insulation Scheme and the Home Upgrade Grant. The company is led by CEO John Kennedy, with founders Tom Lipinski (now CTO) and Professor Peter Childs FREng still associated. Q-Bot plans to use new funding to grow in its main UK market and expand across continental Europe and the USA. Q-Bot develops intelligent robots that remotely apply underfloor insulation beneath suspended floors to improve energy efficiency with minimal disruption. The company offers a Robot-as-a-Service model delivered through a network of Accredited Installation Partners and is TrustMark certified and BBA accredited. Q-Bot has insulated over 2,500 homes to date and works with social and private landlords as well as homeowners. Following a 2021 strategy review, the company is accelerating UK rollout and engaging growing overseas demand. The solution aims to cut heating bills, reduce carbon footprints and tackle fuel poverty while supporting net-zero goals. The business emphasises scalable, cost-effective retrofit delivery using robotics and AI. Q-Bot develops robotic and AI technologies to survey, maintain and upgrade buildings, including a robotic device that applies insulation under suspended floors more cheaply and with less disruption than traditional methods. Its customers include housing associations, local authorities, private homeowners and landlords. The company’s underfloor-insulation solution is BBA-accredited and meets relevant building regulations. Q-Bot was founded in 2012 and is an EMV Capital portfolio company. The business says the technology improves energy efficiency and occupant comfort while avoiding the logistical hassle of ripping up floorboards. Q-Bot plans to use the new funding to accelerate growth, expand its technology portfolio, scale its robotics offering for social landlords, increase sales to private homeowners and enter international markets. Q-BOT Ltd develops a robotics platform that can access, survey, evaluate and apply treatments across a range of industries, initially focused on the building and engineering sector. The platform assists human labour where there are significant cost or health and safety benefits. Its first application is underfloor insulation for Victorian and early-20th century housing, reducing heat loss and improving resident comfort. The platform is extendable to other applications in building and infrastructure industries. Q-BOT intends to use recent funds to continue to grow operations and is funded through a combination of government grants, private investment and sales revenue. The company has been supported by Climate-KIC, The Technology Strategy Board and the Department for Energy and Climate Change and was founded by Professor Peter Childs and Tom Lipinski in Wandsworth, London, UK.